InMed Pharmaceuticals Inc. 8-K Filing Report: Key Updates & Insights

Based on the provided XML section from a financial report, here are the key insights extracted:

1. Entity Information:

• Company Name: InMed Pharmaceuticals Inc.
• CIK (Central Index Key): 0001728328
• SEC File Number: 001-39685
• EIN (Employer Identification Number): 98-1428279
• Headquarters: Suite 1445 - 885 West Georgia Street, Vancouver, CA V6C 3E8
• Contact Number: 604 669-7207

2. Filing Date:

• The report is filed as of February 10, 2025.

3. Filing Type:

• The document type is an 8-K, which is typically used to announce major events that shareholders should know about.

4. Stock Information:

• Common Shares: The company has issued common shares with no par value.
• Ticker Symbol: INM
• Exchange: The shares are traded on NASDAQ.

5. Unit of Measurement:

• Financial figures are reported in USD (U.S. Dollars).
• Shares are also indicated as a measure, suggesting that some financial metrics or calculations may be expressed in terms of share value.

6. Context and Reporting Unit:

• The report references a specific context with an identifier (AsOf2025-02-10), indicating that the information pertains to that specific date.
• There are indications of the measurement units, including USD for monetary values and shares for stock metrics.

Conclusion:

This section provides essential details about InMed Pharmaceuticals Inc. regarding its corporate identity, stock information, and the context of the financial filing. The 8-K filing type suggests that there could be significant developments or changes that warrant disclosure. Further examination of the entire report would be necessary to understand the specific events or financial data being reported.